Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients

A nationwide data survey and propensity analysis

Cho Kai Wu, Yao Hsu Yang, Jyh Ming Jimmy Juang, Yi Chih Wang, Chia Ti Tsai, Ling Ping Lai, Juey Jen Hwang, Fu Tien Chiang, Pau Chung Chen, Jiunn Lee Lin, Lian Yu Lin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Long-term benefit of using a renin-angiotensin-aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of ACEI or ARB use in dialysis patients. We performed a population-based cohort study with time-to-event analyses to estimate the relation between the use of ACEI/ARB and their outcomes. We used a nationwide database (Registry for Catastrophic Illnesses) for Taiwan, which has data from 1995 to 2008 nearly of all patients who received dialysis therapy. The records of all dialysis patients aged ?18 with no evidence of cardiovascular (CV) events in 1997 and 1998 (133,564 patients) were examined. Users (n=50,961) and nonusers (n=59,913) of an ACEI/ARB were derived. We then used propensity score matching and Cox proportional hazards regression models to estimate adjusted hazard ratios (HRs) for all-cause mortality and CV events in users and nonusers of an ACRI/ARB. The 15,182 patients, who used an ACEI/ARB, and the 15,182 nonusers had comparable baseline characteristics during the 14 years of follow-up. The mortality was significantly greater in patients who did not use an ACEI/ARB (HR=0.90, 95% confidence interval=0.86-0.93). Subgroup analysis of 3 tertiles of patients who used different total amounts of ACEI/ARB during the study period indicated that CV events were more common in patients who used an ACEI/ARB for a short duration (tertile 1: HR=1.63), but less common in those who used an ACEI/ARB for long durations (tertile 2: HR=1.05; tertile 3: HR=0.94; trend for declining HR from tertile 1 to 3: P<0.001). The mortality benefit provided by use of an ACEI/ARB was consistent across most patient subgroups, as was the benefit of ARB monotherapy rather than ACEI monotherapy. Independent of traditional risk factors, overall mortality was significantly lower in dialysis patients who used an ACEI/ARB. In addition, subjects who used an ACEI/ARB for longer durations were significantly less likely to experience CV events.

Original languageEnglish
Pages (from-to)e424
JournalMedicine (United States)
Volume94
Issue number3
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Angiotensin Receptors
Angiotensin Receptor Antagonists
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Dialysis
Mortality
Surveys and Questionnaires
Catastrophic Illness
Propensity Score
Renin-Angiotensin System
Taiwan
Proportional Hazards Models
Registries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients : A nationwide data survey and propensity analysis. / Wu, Cho Kai; Yang, Yao Hsu; Juang, Jyh Ming Jimmy; Wang, Yi Chih; Tsai, Chia Ti; Lai, Ling Ping; Hwang, Juey Jen; Chiang, Fu Tien; Chen, Pau Chung; Lin, Jiunn Lee; Lin, Lian Yu.

In: Medicine (United States), Vol. 94, No. 3, 01.01.2015, p. e424.

Research output: Contribution to journalArticle

Wu, Cho Kai ; Yang, Yao Hsu ; Juang, Jyh Ming Jimmy ; Wang, Yi Chih ; Tsai, Chia Ti ; Lai, Ling Ping ; Hwang, Juey Jen ; Chiang, Fu Tien ; Chen, Pau Chung ; Lin, Jiunn Lee ; Lin, Lian Yu. / Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients : A nationwide data survey and propensity analysis. In: Medicine (United States). 2015 ; Vol. 94, No. 3. pp. e424.
@article{b613dd78b3ba43fd90b69fa19d3405d0,
title = "Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: A nationwide data survey and propensity analysis",
abstract = "Long-term benefit of using a renin-angiotensin-aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of ACEI or ARB use in dialysis patients. We performed a population-based cohort study with time-to-event analyses to estimate the relation between the use of ACEI/ARB and their outcomes. We used a nationwide database (Registry for Catastrophic Illnesses) for Taiwan, which has data from 1995 to 2008 nearly of all patients who received dialysis therapy. The records of all dialysis patients aged ?18 with no evidence of cardiovascular (CV) events in 1997 and 1998 (133,564 patients) were examined. Users (n=50,961) and nonusers (n=59,913) of an ACEI/ARB were derived. We then used propensity score matching and Cox proportional hazards regression models to estimate adjusted hazard ratios (HRs) for all-cause mortality and CV events in users and nonusers of an ACRI/ARB. The 15,182 patients, who used an ACEI/ARB, and the 15,182 nonusers had comparable baseline characteristics during the 14 years of follow-up. The mortality was significantly greater in patients who did not use an ACEI/ARB (HR=0.90, 95{\%} confidence interval=0.86-0.93). Subgroup analysis of 3 tertiles of patients who used different total amounts of ACEI/ARB during the study period indicated that CV events were more common in patients who used an ACEI/ARB for a short duration (tertile 1: HR=1.63), but less common in those who used an ACEI/ARB for long durations (tertile 2: HR=1.05; tertile 3: HR=0.94; trend for declining HR from tertile 1 to 3: P<0.001). The mortality benefit provided by use of an ACEI/ARB was consistent across most patient subgroups, as was the benefit of ARB monotherapy rather than ACEI monotherapy. Independent of traditional risk factors, overall mortality was significantly lower in dialysis patients who used an ACEI/ARB. In addition, subjects who used an ACEI/ARB for longer durations were significantly less likely to experience CV events.",
author = "Wu, {Cho Kai} and Yang, {Yao Hsu} and Juang, {Jyh Ming Jimmy} and Wang, {Yi Chih} and Tsai, {Chia Ti} and Lai, {Ling Ping} and Hwang, {Juey Jen} and Chiang, {Fu Tien} and Chen, {Pau Chung} and Lin, {Jiunn Lee} and Lin, {Lian Yu}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000000424",
language = "English",
volume = "94",
pages = "e424",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients

T2 - A nationwide data survey and propensity analysis

AU - Wu, Cho Kai

AU - Yang, Yao Hsu

AU - Juang, Jyh Ming Jimmy

AU - Wang, Yi Chih

AU - Tsai, Chia Ti

AU - Lai, Ling Ping

AU - Hwang, Juey Jen

AU - Chiang, Fu Tien

AU - Chen, Pau Chung

AU - Lin, Jiunn Lee

AU - Lin, Lian Yu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Long-term benefit of using a renin-angiotensin-aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of ACEI or ARB use in dialysis patients. We performed a population-based cohort study with time-to-event analyses to estimate the relation between the use of ACEI/ARB and their outcomes. We used a nationwide database (Registry for Catastrophic Illnesses) for Taiwan, which has data from 1995 to 2008 nearly of all patients who received dialysis therapy. The records of all dialysis patients aged ?18 with no evidence of cardiovascular (CV) events in 1997 and 1998 (133,564 patients) were examined. Users (n=50,961) and nonusers (n=59,913) of an ACEI/ARB were derived. We then used propensity score matching and Cox proportional hazards regression models to estimate adjusted hazard ratios (HRs) for all-cause mortality and CV events in users and nonusers of an ACRI/ARB. The 15,182 patients, who used an ACEI/ARB, and the 15,182 nonusers had comparable baseline characteristics during the 14 years of follow-up. The mortality was significantly greater in patients who did not use an ACEI/ARB (HR=0.90, 95% confidence interval=0.86-0.93). Subgroup analysis of 3 tertiles of patients who used different total amounts of ACEI/ARB during the study period indicated that CV events were more common in patients who used an ACEI/ARB for a short duration (tertile 1: HR=1.63), but less common in those who used an ACEI/ARB for long durations (tertile 2: HR=1.05; tertile 3: HR=0.94; trend for declining HR from tertile 1 to 3: P<0.001). The mortality benefit provided by use of an ACEI/ARB was consistent across most patient subgroups, as was the benefit of ARB monotherapy rather than ACEI monotherapy. Independent of traditional risk factors, overall mortality was significantly lower in dialysis patients who used an ACEI/ARB. In addition, subjects who used an ACEI/ARB for longer durations were significantly less likely to experience CV events.

AB - Long-term benefit of using a renin-angiotensin-aldosterone system blocker such as an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) for patients already receiving dialysis remains undetermined. The aim of this study is to assess the efficacy and safety of ACEI or ARB use in dialysis patients. We performed a population-based cohort study with time-to-event analyses to estimate the relation between the use of ACEI/ARB and their outcomes. We used a nationwide database (Registry for Catastrophic Illnesses) for Taiwan, which has data from 1995 to 2008 nearly of all patients who received dialysis therapy. The records of all dialysis patients aged ?18 with no evidence of cardiovascular (CV) events in 1997 and 1998 (133,564 patients) were examined. Users (n=50,961) and nonusers (n=59,913) of an ACEI/ARB were derived. We then used propensity score matching and Cox proportional hazards regression models to estimate adjusted hazard ratios (HRs) for all-cause mortality and CV events in users and nonusers of an ACRI/ARB. The 15,182 patients, who used an ACEI/ARB, and the 15,182 nonusers had comparable baseline characteristics during the 14 years of follow-up. The mortality was significantly greater in patients who did not use an ACEI/ARB (HR=0.90, 95% confidence interval=0.86-0.93). Subgroup analysis of 3 tertiles of patients who used different total amounts of ACEI/ARB during the study period indicated that CV events were more common in patients who used an ACEI/ARB for a short duration (tertile 1: HR=1.63), but less common in those who used an ACEI/ARB for long durations (tertile 2: HR=1.05; tertile 3: HR=0.94; trend for declining HR from tertile 1 to 3: P<0.001). The mortality benefit provided by use of an ACEI/ARB was consistent across most patient subgroups, as was the benefit of ARB monotherapy rather than ACEI monotherapy. Independent of traditional risk factors, overall mortality was significantly lower in dialysis patients who used an ACEI/ARB. In addition, subjects who used an ACEI/ARB for longer durations were significantly less likely to experience CV events.

UR - http://www.scopus.com/inward/record.url?scp=84922290749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922290749&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000000424

DO - 10.1097/MD.0000000000000424

M3 - Article

VL - 94

SP - e424

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 3

ER -